Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common stock, par value $0.00001 per share
-
Shares outstanding
-
52.9M
-
Number of holders
-
72
-
Total 13F shares, excl. options
-
38.2M
-
Shares change
-
+2.7M
-
Total reported value, excl. options
-
$2.34B
-
Value change
-
+$192M
-
Number of buys
-
51
-
Number of sells
-
-23
-
Price
-
$61.51
Significant Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) as of Q4 2020
84 filings reported holding PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share as of Q4 2020.
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) has 72 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.2M shares
of 52.9M outstanding shares and own 72.18% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (7.33M shares), INTERWEST VENTURE MANAGEMENT CO (6.47M shares), Euclidean Capital LLC (4.18M shares), VIKING GLOBAL INVESTORS LP (2.36M shares), Avoro Capital Advisors LLC (2.35M shares), BOXER CAPITAL, LLC (2.27M shares), RA CAPITAL MANAGEMENT, L.P. (1.71M shares), BlackRock Inc. (1.35M shares), WELLINGTON MANAGEMENT GROUP LLP (1.31M shares), and VANGUARD GROUP INC (1.16M shares).
This table shows the top 72 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.